Latest Ratios: P/E Ratio 8.6x · EV/EBITDA 2.5x · ROE 9.0%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $166M | $675M | $421M | $543M | $356M | $1.2B | $839M | $447M | $704M | $634M | — |
| Enterprise Value | $205M | $714M | $329M | $558M | $377M | $1.3B | $839M | $487M | $742M | $651M | — |
| P/E Ratio → | 8.60 | 34.53 | — | 109.65 | 22.42 | 13.20 | 50.20 | — | — | — | — |
| P/S Ratio | 0.29 | 1.20 | 0.87 | 1.25 | 0.79 | 2.64 | 2.48 | 1.71 | 3.64 | — | — |
| P/B Ratio | 0.39 | 1.55 | 1.09 | 1.95 | 1.34 | 5.12 | 5.91 | 8.03 | 14.96 | 2.13 | — |
| P/FCF | — | — | 100.90 | 82.85 | — | 40.15 | — | — | — | — | — |
| P/OCF | — | — | 29.66 | 17.56 | 14.33 | 19.93 | 153.41 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.27 | 0.68 | 1.29 | 0.84 | 2.68 | 2.48 | 1.87 | 3.83 | — | — |
| EV / EBITDA | 2.48 | 8.62 | 20.90 | 15.51 | 9.36 | 14.10 | 24.05 | — | — | 628.65 | — |
| EV / EBIT | 3.67 | 15.20 | — | 44.34 | 16.93 | 17.82 | 28.89 | — | — | — | — |
| EV / FCF | — | — | 78.81 | 85.14 | — | 40.75 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.6% | 75.6% | 76.0% | 75.4% | 76.7% | 75.6% | 74.2% | 70.9% | 64.4% | — | — |
| Operating Margin | 9.9% | 9.9% | -0.3% | 2.9% | 4.9% | 15.5% | 7.9% | -11.4% | -26.7% | — | — |
| Net Profit Margin | 6.6% | 6.6% | 0.2% | 1.1% | 3.4% | 20.2% | 5.1% | -14.8% | -33.5% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.0% | 9.0% | 0.3% | 1.8% | 6.1% | 49.2% | 17.5% | -75.4% | -37.6% | -0.7% | -0.1% |
| ROA | 6.8% | 6.8% | 0.2% | 1.1% | 3.5% | 25.7% | 6.7% | -20.1% | -27.2% | -0.7% | -0.1% |
| ROIC | 10.9% | 10.9% | -0.3% | 3.2% | 6.1% | 27.0% | 16.8% | -24.7% | -19.3% | -1.1% | 0.1% |
| ROCE | 12.2% | 12.2% | -0.3% | 3.3% | 6.1% | 24.8% | 14.0% | -23.1% | -25.4% | -1.5% | 0.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.31 | 0.31 | 0.11 | 0.43 | 0.47 | 0.55 | 0.60 | 1.81 | 1.26 | 0.06 | — |
| Debt / EBITDA | 1.60 | 1.60 | 2.75 | 3.32 | 3.07 | 1.49 | 2.43 | — | — | 17.24 | — |
| Net Debt / Equity | — | 0.09 | -0.24 | 0.05 | 0.08 | 0.08 | 0.00 | 0.73 | 0.81 | 0.06 | -0.00 |
| Net Debt / EBITDA | 0.47 | 0.47 | -5.86 | 0.42 | 0.53 | 0.21 | 0.01 | — | — | 17.11 | -0.14 |
| Debt / FCF | — | — | -22.09 | 2.29 | — | 0.60 | — | — | — | — | — |
| Interest Coverage | — | — | -0.82 | 5.75 | 11.10 | 9.72 | 2.57 | -3.29 | -4.97 | -0.82 | -0.04 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.62 | 3.62 | 3.69 | 2.80 | 2.97 | 2.74 | 2.56 | 2.10 | 1.07 | 0.07 | 3.00 |
| Quick Ratio | 3.32 | 3.32 | 3.35 | 2.44 | 2.64 | 2.44 | 2.15 | 1.71 | 0.87 | 0.07 | 3.00 |
| Cash Ratio | 0.94 | 0.94 | 1.75 | 1.30 | 1.37 | 1.38 | 1.24 | 1.00 | 0.32 | 0.03 | 2.17 |
| Asset Turnover | — | 0.94 | 0.97 | 0.94 | 1.00 | 1.05 | 1.17 | 1.18 | 1.18 | — | — |
| Inventory Turnover | 4.64 | 4.64 | 4.41 | 3.77 | 4.24 | 4.56 | 3.14 | 3.31 | 5.17 | — | — |
| Days Sales Outstanding | — | 140.97 | 83.19 | 69.10 | 72.41 | 64.40 | 61.29 | 55.05 | 64.30 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.4% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | 208.8% | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 11.6% | 2.9% | — | 0.9% | 4.5% | 7.6% | 2.0% | — | — | — | — |
| FCF Yield | — | — | 1.0% | 1.2% | — | 2.5% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 6.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.5% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 6.5% | 0.0% | 0.0% | 0.0% | 0.0% | 1.5% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $130M | $132M | $133M | $132M | $134M | $111M | $93M | $69M | $64M | $9M |
Includes 30+ ratios · 10 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ORGO stock.
Organogenesis Holdings Inc.'s current P/E ratio is 8.6x. The historical average is 46.0x.
Organogenesis Holdings Inc.'s current EV/EBITDA is 2.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.4x.
Organogenesis Holdings Inc.'s return on equity (ROE) is 9.0%. The historical average is -3.0%.
Based on historical data, Organogenesis Holdings Inc. is trading at a P/E of 8.6x. Compare with industry peers and growth rates for a complete picture.
Organogenesis Holdings Inc. has 75.6% gross margin and 9.9% operating margin.
Organogenesis Holdings Inc.'s Debt/EBITDA ratio is 1.6x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Reimbursement and regulatory volatility
Metrics are mathematically derived from official filings.
Market Valuation Reflects Reimbursement Uncertainty
As reported in recent financial filings, the company trades at an EV/EBITDA multiple of 4.25x, which appears to discount the inherent regulatory risks of the regenerative medicine sector compared to broader medtech peers that often command significantly higher premiums in the current market environment.
The low P/S ratio of 0.56 suggests that investors are skeptical regarding the long-term sustainability of current revenue levels, likely due to the ongoing flux in Medicare reimbursement policies. This valuation implies that the market is pricing in a high probability of margin compression rather than rewarding the company for its specialized biologic portfolio.
Capital Efficiency Subject to Volatility
Based on the provided data, ROIC has fluctuated from a peak of 11.7% in 2025Q4 to a negative 11.7% in 2026Q1, indicating that the company struggles to consistently compound capital due to the high fixed costs associated with its specialized manufacturing and cold-chain distribution infrastructure.
The erratic nature of these returns suggests that the company's ability to generate value is highly sensitive to quarterly volume shifts and potential inventory write-downs. Investors should monitor whether management can stabilize these returns as they navigate the transition toward more restrictive reimbursement frameworks.
Working Capital Cycles Impede Efficiency
According to the latest quarterly data, the cash conversion cycle reached 401 days in 2026Q1, a significant departure from the 76-day cycle observed in 2025Q4, which highlights the operational challenges of managing perishable inventory and the timing of receivables within the complex US healthcare reimbursement system.
The dramatic spike in the CCC suggests that the company's working capital management is currently inefficient, potentially due to supply chain bottlenecks or delays in insurance claims processing. This volatility in asset turnover warrants further investigation into whether the company can maintain its high-touch sales model without further straining its liquidity.
Misapplication of Standard P/E Multiples
As indicated by the company's volatile earnings history, the P/E ratio is a misleading metric for Organogenesis because it fails to account for the significant non-cash charges and reimbursement-related adjustments that frequently distort net income, making it a poor proxy for the company's true underlying earning power.
Analysts should instead focus on adjusted EBITDA or free cash flow metrics, which better capture the cash-generating potential of the business after accounting for the high costs of maintaining a direct sales force. Relying on P/E ignores the structural reality that this firm is a high-barrier biologic manufacturer rather than a traditional, stable-margin medical device company.